Jerel is a Managing Director at Versant Venture Management, LLC, a healthcare investment firm. He has played a critical role in Versant’s company creation strategies and has been heavily involved in a number of public and private biotech companies such as Quanticel (sale), Crispr (CRSP), Inception 4 (sale), Inception 5 (sale), Northern (sale), BlueRock (sale), Repare (RPTX), Akero (AKRO), Chinook, Turnstone, Ventus, and Tentarix. Jerel was promoted to Managing Director at Versant in 2016.
Prior to joining Versant, Jerel was an Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the U.S., Europe, China, and Russia. Jerel earned his doctorate from Stanford University, where he also completed his post-doctoral research.